Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open-label Study of the Efficacy, Pharmacokinetica and Safety of Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

NCT05783882 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT05783882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05783882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open-label Study of the Efficacy, Pharmacokinetica and Safety of Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Unknown status
Start date
February 1, 2022
Completion date
June 30, 2023
Enrollment
114 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable or metastatic melanoma